CRISPR-based compositions for treating vascular disorders
AssigneesThe Administrators of the Tulane Educational Fund, National Institutes of Health (Nih), U.S. Dept. of Health and Human Services (Dhhs), U.S. Government
InventorsShusheng Wang, Bo Yu
Life of this patent
Estimating the term…
Abstract
CRISPR-based compositions and methods of their use to impair or promote angiogenesis in a patient to treat indications including, but not limited to, tumor growth, age-related macular degeneration, and metastasis. Single-guide ribonucleic acids sg-RNA-1 (SEQ ID NO: 2) or sg-RNA-2 (SEQ ID NO: 3) are shown to affect angiogenesis.
Claims3
A composition comprising an antagonist of each of lncEGFL7OS, EGFL7, and miR-126 function in a pharmaceutically acceptable buffer, diluent or medium, wherein the antagonist is a single guide RNA (sg-RNA) plus dead Cas9-Krüppel associated box (dCas9-KRAB), wherein said sg-RNA is sg-RNA-1 (SEQ ID NO:
- 2) or sg-RNA-2 (SEQ ID NO:
- 3).
Dependencies are inferred from the claim text.